Kidney360 Publish Ahead of Print, published on February 3, 2021 as doi:10.34067/KID.0000472021 Lower urinary tract symptoms should be queried when initiating Sodium Glucose Co- Transporter 2 inhibitors Nicolas Krepostman and Holly Kramer 1Departments of Medicine and 2Public Health Sciences, Loyola University Chicago. Maywood, IL Corresponding Author: Holly Kramer MD MPH Loyola University Chicago 2160 S. First Avenue Maywood, IL 60153 Fax 708-216-8296 Office 708-327-9039 Email:
[email protected] 1 Copyright 2021 by American Society of Nephrology. The sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce risk of both macrovascular (myocardial infractions and stroke) (1) and microvascular events (progression of chronic kidney disease) (2) in persons with type 2 diabetes. The beneficial effects of SGLT2i are derived from a cascade of effects subsequent to inhibition of glucose reabsorption in the S1 segment of the proximal tubule. Clinical trials have shown that SGLT2i reduce the absolute risk of kidney failure by 35% relative to placebo (95% CI 54%, 81%).(2) Thus, SGLT2i may be one of the most important interventions provided for adults at high risk for kidney failure. With any intervention, side effects and adverse effects must be considered in order to identify patients appropriate for the intervention and ensure that treated patients are educated regarding potential side effects and the appropriate coping mechanisms for bothersome side effects. For the SGLT2i drug class, adverse events includes hypoglycemia, ketoacidosis, volume depletion (especially when combined with loop diuretics), and genital urinary infections.(3-6) Other important side effects that are not life threatening but nevertheless bothersome are lower urinary tract symptoms (LUTS).